Abstract
Introduction: The fentanyl HCl patient-controlled transdermal system (PCTS) is a self-contained, preprogrammed, needle-free system currently in development for acute pain management in a medically supervised setting. The objectives of these studies were to evaluate skin application sites for the fentanyl HCl PCTS and to evaluate the effect of patient demographics on its pharmacokinetics.
Methods: The first study was a randomised, open-label, single-centre, 3-treatment, crossover study in which the fentanyl HCl PCTS was applied to the upper outer arm, lower inner arm or chest of healthy volunteers. Fentanyl 25μg was then delivered via this system twice during the first 20 minutes of every hour for 24 hours. The pharmacokinetics of fentanyl were determined and analysed for each application site using ANOVA. The second study was a nonrandomised, nonblind, multicentre, sequential treatment study. Healthy volunteers received fentanyl HCl 40μg via the PCTS three times during the first 30 minutes of each hour for 3 hours. After a 5- to 10-day washout period, fentanyl HCl 120μg was administered intravenously during the first 30 minutes of each hour for 3 hours as a reference treatment. Pharmacokinetic parameters were determined for the fentanyl HCl PCTS, and results were analysed using ANOVA. Safety and tolerability were evaluated in both studies.
Results: Application of the system to the upper outer arm or chest resulted in similar maximum serum concentrations (Cmax; 1.193 and 1.176 μg/L, respectively) and areas under the serum concentration-time curve (AUC24–25; 1.033 and 1.015 μg · h/L). However, both Cmax and AUC24-25 were less when the system was applied to the lower inner arm (0.859 μg/L and 0.757 μg · h/L). Subject age, bodyweight, sex and ethnicity had no significant effect on pharmacokinetic parameters. No serious adverse events were reported in either study during or after administration of the fentanyl HCl PCTS.
Conclusion: Fentanyl HCl is comparably absorbed from the PCTS when it is applied to the upper outer arm or chest. The pharmacokinetics of fentanyl HCl delivered by the PCTS are unaffected by sex, age, race or weight.
Similar content being viewed by others
References
Chelly JE, Grass J, Houseman TW, et al. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter placebo-controlled trial. Anesth Analg 2004; 98: 427–33
Brown CR, Moodie JE, Bisley EJ, et al. Dose-ranging study of Transfenta for postoperative pain [abstract no. 888]. 17th Annual Scientific Meeting of the American Pain Society; 1998 Nov 5–8; San Diego, CA
Moodie J, Brown C, Bisley E, et al. Efficacy and safety of Transfenta in the management of postoperative pain on days 1, 2 and 3 after surgery [abstract no. 887]. 17th Annual Scientific Meeting of the American Pain Society; 1998 Nov 5–8; San Diego, CA
Moodie, J, Brown C, Jones S, et al. Efficacy and safety of Transfenta, a transdermal electrotransport system for the management of postoperative pain following short-stay surgical procedures [abstract no. 844]. 17th Annual Scientific Meeting of the American Pain Society; 1998 Nov 5–8; San Diego, CA
Gupta S, Bernstein K, Noorduin H, et al. Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. J Clin Pharmacol 1998; 38: 951–8
Data on file, ALZA Corporation, 2003
Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61: 2289–307
Data on file, ALZA Corporation, 2003
Harrison LL, Harari D. An evaluation of bioequivalence of two 7-day 17beta-estradiol transdermal delivery systems by anatomical site. J Clin Pharmacol 2002; 42: 1134–41
Gyory RJ, Phipps JB. Effect of current density and current duration on the membrane resistance of skin. In: Couvreur P, Duchene D, Green P, Juninger HE, editors. Transdermal administration: a case study-iontophoresis. Paris: Editions de Sante, 1997: 262–5
Data on file, ALZA Corporation, 2003
Acknowledgments
This study was funded by ALZA Corporation and the authors are employees of ALZA Corporation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gupta, S.K., Hwang, S., Southam, M. et al. Effects of Application Site and Subject Demographics on the Pharmacokinetics of Fentanyl HCl Patient-Controlled Transdermal System (PCTS). Clin Pharmacokinet 44 (Suppl 1), 25–32 (2005). https://doi.org/10.2165/00003088-200544001-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200544001-00005